Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
AssigneesRamot at Tel-Aviv University Ltd., Ccam Biotherapeutics Ltd.
InventorsGal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
Claims24
1-56. (canceled)
A monoclonal antibody or an antibody fragment thereof which recognizes human CEACAM1 having a heavy-chain CDR1 comprising a sequence set forth in SEQ ID NO:
- 1, a heavy-chain CDR2 comprising a sequence set forth in SEQ ID NO:
- 2 a heavy-chain CDR3 comprising a sequence set forth in SEQ ID NO:
- 3, a light-chain CDR1 comprising a sequence set forth in SEQ ID NO:
- 4, a light-chain CDR2 comprising a sequence set forth in SEQ ID NO:
- 5 and a light-chain CDR3 comprising a sequence set forth in SEQ ID NO:
- 6, and analogs and derivatives thereof.
A monoclonal antibody which recognizes CEACAM1 produced from DNA sequences of the heavy and light chains contained in a plasmid deposited on Sep. 28, 2011 under ATCC Accession Number PTA-12130.
A monoclonal antibody which recognizes CEACAM1, or a fragment thereof comprising at least the antigen-binding portion, which is capable of binding the same epitope on the CEACAM1 molecule to which a monoclonal antibody having the six CDR sequences set forth in SEQ ID NOs:
- 7, 8, 9, 10, 11 and 12, or the six CDR sequences set forth in SEQ ID NOs:
- 13, 14, 15, 16, 17 and 18, binds.
Dependencies are inferred from the claim text.